CSIMarket
 


Adamas Pharmaceuticals Inc  (ADMS)
Other Ticker:  
 
 

ADMS's Revenue Growth by Quarter and Year

Adamas Pharmaceuticals Inc's Revenue results by quarter and year




ADMS Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 21.01 16.35 13.32
III Quarter September 25.90 20.18 13.93 10.61
II Quarter June 21.97 18.79 12.69 7.57
I Quarter March 19.31 14.48 11.67 2.55
FY   67.18 74.46 54.64 34.05



ADMS Revenue third quarter 2021 Y/Y Growth Comment
Adamas Pharmaceuticals Inc reported Revenue improvement of 28.33% year on year in the third quarter 2021, to $ 25.90 millions, this is lower than Adamas Pharmaceuticals Inc's recent average Revenue surge of 55510.81%.

Looking into third quarter 2021 results within Major Pharmaceutical Preparations industry 90 other companies have achieved higher Revenue growth. While Adamas Pharmaceuticals Inc' s Revenue rise of 28.33% ranks overall at the positon no. 1238 in the third quarter 2021.




ADMS Revenue ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 28.5 % 22.75 % 2236.84 %
III Quarter September 28.33 % 44.87 % 31.29 % -
II Quarter June 16.92 % 48.07 % 67.64 % -
I Quarter March 33.36 % 24.08 % 357.65 % -
FY   - 36.27 % 60.47 % 5873.68 %

Financial Statements
Adamas Pharmaceuticals Inc's third quarter 2021 Revenue $ 25.90 millions ADMS's Income Statement
Adamas Pharmaceuticals Inc's third quarter 2020 Revenue $ 20.18 millions Quarterly ADMS's Income Statement
New: More ADMS's historic Revenue Growth >>


ADMS Revenue (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 4.11 % 17.37 % 25.54 %
III Quarter September 17.87 % 7.4 % 9.77 % 40.16 %
II Quarter June 13.78 % 29.77 % 8.74 % 196.86 %
I Quarter March -8.09 % -11.44 % -12.39 % 347.37 %
FY (Year on Year)   - 36.27 % 60.47 % 5873.68 %




Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #91
Healthcare Sector #201
Overall #1238

Revenue Y/Y Growth Statistics
High Average Low
1061200 % 55510.81 % -100 %
(Sep 30 2018)   (Mar 31 2017)
Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #91
Healthcare Sector #201
Overall #1238
Revenue Y/Y Growth Statistics
High Average Low
1061200 % 55510.81 % -100 %
(Sep 30 2018)   (Mar 31 2017)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Adamas Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
56700 % 2938.35 % -100 %
(Dec 31 2017)  


ADMS's III. Quarter Q/Q Revenue Comment
Adamas Pharmaceuticals Inc achieved in the III. Quarter 2021 below company average Revenue jump of 17.87% quarter on quarter, to $ 25.90 millions.

Although the III. Quarter 2021 ADMS's performance was below the ordinary , that has been yet good story, as the current surge, eclipses the 7.4% rise in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Adamas Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 618.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #125
Overall #618
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #125
Overall #618
Revenue Q/Q Growth Statistics
High Average Low
56700 % 2938.35 % -100 %
(Dec 31 2017)  


ADMS's III. Quarter Q/Q Revenue Comment
Adamas Pharmaceuticals Inc achieved in the III. Quarter 2021 below company average Revenue jump of 17.87% quarter on quarter, to $ 25.90 millions.

III. Quarter 2021 Adamas Pharmaceuticals Inc's performance were contradictory, albeit below the average, yet it demonstrates a quite improvement compare to the 7.4% in the III. Quarter a year ago Margaux Jacobs, an industry insider located in Paris said.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Adamas Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 618.


Adamas Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
Cumulative Revenue 12 Months Ending $ 88.19 $ 82.47 $ 79.29 $ 74.46 $ 69.80
Y / Y Revenue Growth (TTM) 26.35 % 29.76 % 38.01 % 36.28 % 35.26 %
Year on Year Revenue Growth Overall Ranking # 965 # 857 # 329 # 237 # 224
Seqeuential Revenue Change (TTM) 6.94 % 4.01 % 6.49 % 6.68 % 9.82 %
Seq. Revenue Growth (TTM) Overall Ranking # 1043 # 1857 # 1078 # 529 # 2359




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Adamas Pharmaceuticals Inc's cumulative twelve months Revenue were $ 88 millions, company would post below average annual Revenue growth of 9.82% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Adamas Pharmaceuticals Inc's Revenue growth from the 21.97% growth in Jun 30 2021.

In the Healthcare sector 185 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 857 to 965.

Revenue TTM Q/Q Growth Statistics
High Average Low
26.76 %
-5.09 %
-93.95 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 60
Healthcare Sector # 186
Overall # 965

Revenue TTM Y/Y Growth Statistics
High Average Low
1281.5 %
91.22 %
-96.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 177
S&P 500 # 1043
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Adamas Pharmaceuticals Inc's cumulative twelve months Revenue were $ 88 millions, company would post below average annual Revenue growth of -96.66% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Adamas Pharmaceuticals Inc's Revenue growth from the 21.97% growth in Jun 30 2021.

In the Healthcare sector 185 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 857 to 965.

Revenue TTM Q/Q Growth Statistics
High Average Low
26.76 %
-5.09 %
-93.95 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 60
Healthcare Sector # 186
Overall # 965

Revenue TTM Y/Y Growth Statistics
High Average Low
1281.5 %
91.22 %
-96.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 60
Sector # 177
S&P 500 # 1043




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADMS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ADMS's Competitors
Revenue Growth for Adamas Pharmaceuticals Inc's Suppliers
Revenue Growth for ADMS's Customers

You may also want to know
ADMS's Annual Growth Rates ADMS's Profitability Ratios ADMS's Asset Turnover Ratio ADMS's Dividend Growth
ADMS's Roe ADMS's Valuation Ratios ADMS's Financial Strength Ratios ADMS's Dividend Payout Ratio
ADMS's Roa ADMS's Inventory Turnover Ratio ADMS's Growth Rates ADMS's Dividend Comparisons



Companies with similar Revenue jump for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2021
Alnylam Pharmaceuticals Inc 49.09%$ 49.089 millions
1life Healthcare Inc 48.85%$ 48.852 millions
Syros Pharmaceuticals Inc 48.82%$ 48.824 millions
La Jolla Pharmaceutical Company46.76%$ 46.759 millions
Cutera Inc 46.64%$ 46.642 millions
Aerie Pharmaceuticals Inc 45.97%$ 45.974 millions
Epizyme Inc.45.85%$ 45.850 millions
Biolase Inc 45.76%$ 45.756 millions
Tandem Diabetes Care Inc 45.33%$ 45.326 millions
Acutus Medical Inc 45.00%$ 45.005 millions
Mannkind Corporation44.68%$ 44.678 millions
Tela Bio Inc 44.06%$ 44.062 millions
American Shared Hospital Services43.77%$ 43.774 millions
Htg Molecular Diagnostics Inc41.83%$ 41.827 millions
Iradimed Corporation41.67%$ 41.670 millions
Caredx Inc 41.63%$ 41.635 millions
T2 Biosystems Inc 41.62%$ 41.621 millions
Optinose Inc 41.40%$ 41.397 millions
Global Blood Therapeutics Inc.41.10%$ 41.104 millions
Kymera Therapeutics Inc 39.93%$ 39.930 millions
Avita Medical Inc 38.74%$ 38.735 millions
Align Technology inc 38.38%$ 38.380 millions
Immucell Corp38.35%$ 38.352 millions
Kala Bio inc 38.15%$ 38.153 millions
Precipio inc 38.05%$ 38.045 millions
Pieris Pharmaceuticals Inc 38.04%$ 38.040 millions
Co diagnostics Inc 37.96%$ 37.961 millions
Qualigen Therapeutics Inc 37.88%$ 37.883 millions
Electrocore Inc 37.59%$ 37.587 millions
Strata Skin Sciences Inc 37.38%$ 37.378 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com